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Abstract 
Background: Massively parallel sequencing of maternal cell-free DNA (cfDNA) is widely used to test fetal genetic 
abnormalities in non-invasive prenatal testing (NIPT). However, sequencing-based approaches are still of high cost. 
Building upon previous knowledge that placenta, the main source of fetal circulating DNA, is hypomethylated in 
comparison to maternal tissue counterparts of cfDNA, we propose that targeting either unmodified or 5-hydroxym-
ethylated CG sites specifically enriches fetal genetic material and reduces numbers of required analytical sequencing 
reads thereby decreasing cost of a test.
Methods: We employed uTOPseq and hmTOP-seq approaches which combine covalent derivatization of unmodified 
or hydroxymethylated CG sites, respectively, with next generation sequencing, or quantitative real-time PCR.
Results: We detected increased 5-hydroxymethylcytosine (5hmC) levels in fetal chorionic villi (CV) tissue samples as 
compared with peripheral blood. Using our previously developed uTOP-seq and hmTOP-seq approaches we obtained 
whole-genome uCG and 5hmCG maps of 10 CV tissue and 38 cfDNA samples in total. Our results indicated that, in 
contrast to conventional whole genome sequencing, such epigenomic analysis highly specifically enriches fetal DNA 
fragments from maternal cfDNA. While both our approaches yielded 100% accuracy in detecting Down syndrome 
in fetuses, hmTOP-seq maintained such accuracy at ultra-low sequencing depths using only one million reads. We 
identified 2164 and 1589 placenta-specific differentially modified and 5-hydroxymethylated regions, respectively, in 
chromosome 21, as well as 3490 and 2002 Down syndrome-specific differentially modified and 5-hydroxymethyl-
ated regions, respectively, that can be used as biomarkers for identification of Down syndrome or other epigenetic 
diseases of a fetus.
Conclusions: uTOP-seq and hmTOP-seq approaches provide a cost-efficient and sensitive epigenetic analysis of fetal 
abnormalities in maternal cfDNA. The results demonstrated that T21 fetuses contain a perturbed epigenome and also 
indicated that fetal cfDNA might originate from fetal tissues other than placental chorionic villi. Robust covalent deri-
vatization followed by targeted analysis of fetal DNA by sequencing or qPCR presents an attractive strategy that could 
help achieve superior sensitivity and specificity in prenatal diagnostics.
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Background
Down syndrome, the trisomy of chromosome 21 (T21), 
is the most common incurable chromosomal aneuploidy 
in live born infants and is associated with physical and 
mental disability [1]. Invasive diagnostic procedures such 
as amniocentesis, chorionic villus sampling or cordocen-
tesis are currently used to confirm the diagnosis of T21, 
commonly by a fetal karyotyping. Although the safety of 
invasive procedures has been improving, a risk of fetal 
loss (0.5 to 1% for chorionic villus sampling and amnio-
centesis) and follow-up infections still remain [2]. Hence, 
to reduce the number of invasive diagnostic procedures, 
non-invasive and highly confident prenatal screening 
tests are still required.
Since the discovery of fetal genomic material in the 
form of circulating cell-free fetal DNA (cffDNA) in the 
blood plasma of pregnant women [3], many efforts have 
been made to employ cffDNA for non-invasive prenatal 
testing (NIPT) of fetal chromosomal aneuploidies. How-
ever, the detection of cffDNA in maternal blood circu-
lation has represented a considerable challenge. Since 
cffDNA comprises only a 6–10% fraction of the total 
maternal cfDNA in first and second trimester pregnan-
cies [4, 5], this can often interfere with the analysis of 
fetal nucleic acids. The issue of the low abundance of 
cffDNA can be overcome by evaluating the dosage of 
chromosome 21 from the ratios of polymorphic alleles 
in the placenta-derived nucleic acid molecules [6]. How-
ever, this approach can only be applied to a subset of the 
population, when fetuses are heterozygous for the tar-
geted polymorphisms.
Massive parallel sequencing (MPS) has been employed 
for the detection of fetal aneuploidy through measuring 
the dosage of any chromosome in maternal plasma. Pre-
vious reports have indicated that cffDNA is shorter than 
its maternal counterpart [7–9]. Therefore, MPS has been 
combined with size fractionation prior to sequencing or 
in silico filtering of cfDNA to enrich for fetal DNA frag-
ments. However, even though MPS has been widely used 
in commercial prenatal testing, such an approach which 
requires deep sequencing, increases the cost of medical 
service.
An alternative approach to improve the cost-effec-
tiveness of NIPT is to preferentially target fetal DNA 
sequences based on their DNA modification differences 
between maternal cfDNA and cffDNA. Bisulfite conver-
sion, methyl-DNA immunoprecipitation (MeDIP) and 
methylation sensitive restriction digestion have already 
been employed for the identification of fetal-specific 
differentially methylated regions that can be used for 
the detection of fetal aneuploidies [10–12]. Although 
bisulfite conversion enables analysis of the methylation 
status of each CG site [13–17], it reinforces degradation 
of cfDNA, further reducing the amount of cffDNA avail-
able for fetal-specific methylome analysis. Furthermore, 
screening genomes by whole-genome bisulfite sequenc-
ing is technologically demanding and extremely expen-
sive leading to an unnecessary increase in cost of NIPT. 
The methyl-DNA immunoprecipitation and methyla-
tion sensitive restriction digestion enrich hypermethyl-
ated fetal-specific DNR regions [10, 11, 18, 19]. However, 
methylation sensitive restriction digestion is inherently 
limited by the sequence-specificity of available enzymes 
which restricts the number of regions suitable for test-
ing. MeDIP enrichment is biased to highly methylated 
sequences [20] and thus, the potential diagnostic infor-
mativeness of the low CG density regions or less methyl-
ated sequences might be lost.
Examination of the differential methylation between 
placenta and maternal blood uncovered significant pla-
cental hypomethylation relative to cfDNA of non-preg-
nant women [13]. These hypomethylated regions have 
low CG and gene density and thus could be poorly cov-
ered by affinity enrichment methods, such as MeDIP. 
Moreover, since the unmodified CG fraction represents 
a smaller portion of the human genome (20–30% of CGs 
are unmethylated in human tissues [21]), its targeted 
analysis could be more relevant for the cost-effective 
NIPT. Therefore, further technological advances are nec-
essary for the identification of effective and stable fetal-
specific biomarkers for aneuploidy diagnostics.
In recent years, covalent derivatization has been 
adapted for epigenome-wide studies of various cyto-
sine modifications [22–25]. Here, we applied for the 
first time the covalent derivatization of unmodified CG 
sites (uCGs) in maternal cfDNA for identification of 
fetal-derived genomic regions. In addition, we detected 
5-hydroxymethylcytosine (5hmC) in placental CV DNA 
samples, and for the first time demonstrated its utility 
for detection of fetal karyotype. We firmly believe that 
both approaches of covalent targeting combined with 
sequencing and innovative bioinformatic data analysis 
or qPCR can vastly reduce the cost and turnaround time, 
increasing the availability of NIPT.
Results
Genome‑wide uCG and 5hmCG patterns suggest strong 
fetal contribution to maternal cfDNA
We sought to identify DNA fragments of fetal origin in 
maternal cfDNA by analyzing unmodified and 5-hydrox-
ymethylated cytosines located in CG dinucleotides (uCG 
and 5hmCG, respectively). In order to test the feasibility 
of 5hmC analysis in cfDNA, we analyzed global amounts 
of 5hmC in two trophoblast-enriched CV tissue and 
three blood DNA samples by a HPLC–MS/MS assay and 
found them to be higher in CV samples (0.021 ± 0.002% 
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of total cytosine) than in blood DNA (0.012 ± 0.002% of 
total cytosine).
For profiling of uCGs and 5hmCGs we employed our 
recently developed uTOP-seq and hmTOP-seq strate-
gies, respectively, which assess the modification status of 
genomic CG sites through selective covalent coupling of a 
priming oligonucleotide to azide-modified CGs and their 
subsequent sequencing [24, 25]. By leveraging the high 
robustness of covalent derivatization and the sensitiv-
ity of such targeted sequencing we successfully adapted 
both strategies for the analysis of nanogram quantities of 
cfDNA.
We constructed uCG and 5hmCG maps of CV tissue 
samples (CVS; n = 7 of uCG and n = 3 of 5hmCG signals) 
and cfDNA samples (n = 38 maps in total). cfDNA sam-
ples consisted of non-pregnant controls (NPC; uCG n = 7 
and 5hmCG n = 7) and pregnant women carrying healthy 
(uCG n = 8 and 5hmCG n = 7) or T21 fetuses (uCG n = 5 
and 5hmCG n = 4). Fetal sex was approximately equally 
distributed across sample groups (Additional file  1: 
Table S1).
In order to test whether uCG and 5hmCG modifica-
tion differences could distinguish between the sample 
groups, we first looked at the total sequencing coverage 
of the uCG and 5hmCG sites (CG-coverage). Mean total 
uCG coverage was different across the three groups of 
samples (p = 7 × 10–4, ANOVA); it was the lowest among 
NPCs and the highest among CVS. Importantly, the 
mean total coverage of the pregnant women cfDNA was 
in between the NPCs and CVS (Fig.  1a). Furthermore, 
the fraction of identified uCGs covered by at least 1 read 
showed a similar but even stronger difference among all 
groups (p = 7.4 × 10–7, ANOVA; Fig. 1b). For the 5hmCG 
samples, total coverage was not informative, but the 
fraction of identified CGs (CG-fraction)  increased from 
NPCs towards CVS (ANOVA p = 0.45 and p = 8.9 × 10–3, 
respectively; Fig.  1a, b). Non-metric multidimensional 
scaling transformation of the uCG and 5hmCG profiles 
confirmed the above observations and revealed substan-
tial modification differences between the sample groups. 
In both cases, cfDNA samples of pregnant women tended 
to concentrate between those of NPCs and CVS, suggest-
ing that they might represent a mixture of the latter two 
groups (Fig. 1c). Considering both higher total coverage 
and higher fraction of covered CG sites, CV tissue is rela-
tively hypomethylated and also shows increased hydroxy-
methylation in comparison to cfDNA of NPCs.
Next, we explored the distribution of the identified 
uCGs and 5hmCGs across genomic elements in all the 
sample groups. We computed total coverage in 1,000-
bp windows genome-wide and tested the enrichment of 
top 10% most covered windows with genomic elements. 
As expected, the hypomethylated regions concentrated 
in CG islands (CGI), promoters of protein coding genes 
and 5′UTRs, while the highly modified 5hmCGs were 
mostly observed in 3′UTRs, exons and introns (Fig. 1d). 
Therefore, both uTOP-seq and hmTOP-seq approaches 
may provide distinct but complementary data for 
detection and analysis of cffDNA fragments in maternal 
circulation.
Epigenetic profiling determines fetal fraction in cfDNA
It is well known that very low or exceptionally high fetal 
fractions in maternal cfDNA may affect the accuracy of 
subsequent NIPT tests [26]. Having established that the 
uTOP-seq and hmTOP-seq signals are higher among 
pregnant women, we further sought to determine the 
correlation between the signal strength and fetal frac-
tion. We first used whole genome sequencing and 
SeqFF algorithm to establish a reference fetal fraction 
in cfDNA samples. SeqFF is a widely used approach 
which relies on an increased proportion of short 
cfDNA fragments, which are more likely of fetal origin, 
and is independent of fetal sex [27]. We applied SeqFF 
on the uTOP-seq and hmTOP-seq data and observed 
high correlation between the predicted and reference 
fetal fractions (Pearson |r|= 0.86, p = 3.2 × 10–4 and 
|r|= 0.9; p = 3.9 × 10–4, for uCG and 5hmCG, respec-
tively; Fig.  2). Importantly, a simple linear regression 
revealed that an increase of the reference fetal fraction 
by 0.01 corresponded to an increase in fetal fraction 
predicted from uCG profiles by 0.079. For 5hmCG data, 
the predicted fetal fraction decreased by 0.226 for every 
0.01 increase of the reference fraction. Interestingly, 
an increasing fetal fraction would acquire increasing 
read counts in uTOP-seq, but decreasing read counts 
in hmTOP-seq. Such inverse relationship in hmTOP-
seq most likely indicates that the regions used by SeqFF 
are highly enriched in uCGs but depleted in 5hmCGs in 
cffDNA.
The results indicated that both uTOP-seq and hmTOP-
seq enable enrichment of fetal circulating DNA from 
maternal cfDNA. Importantly, hmTOP-seq may be more 
sensitive for evaluation of fetal fraction, most likely due 
to the well-known role of tissue specificity of 5hmC [28]. 
Consequently, fewer reads would be necessary to pro-
vide sensitive analysis of fetal fraction and detection of 
fetal abnormalities. To further test this hypothesis, we 
analysed by hmTOP-seq four additional cfDNA samples 
obtaining on average 2.5 million raw reads for each sam-
ple (two healthy and two T21 fetuses). As expected, we 
observed a very high correlation between reference and 
predicted fetal fraction in these samples prepared with 
shallow sequencing depth (Pearson |r|= 0.95, p = 0.05; 
Fig. 2b).
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Chromosome‑wide cfDNA uCG and 5hmCG patterns reveal 
fetal karyotype
We tested whether the total coverage or the fraction of 
identified CGs (CG-coverage and CG-fraction) in chro-
mosome 21 may be used to detect fetal T21 in pregnant 
women. As suggested previously [29], for each sample 
we computed the ratio of total coverage in chromosome 
21 and a reference chromosome. We then estimated the 
mean and standard deviation of these ratios among the 
healthy pregnancies. We assigned a Z-score to each 
sample indicating how far away the sample ratio is 
from the expected ratio of healthy pregnancies. Identi-
cal approach was applied for Z-score calculations using 
CG-fractions. Next, we trained a logistic regression 
model using Z-score as the independent variable and 
fetal karyotype as the dependent variable and estimated 
predictive accuracy of the model using a leave-one-out 
cross-validation technique. We found that using chro-
mosome 16 for uCG and chromosome 20 for 5hmCG 
signal as a reference, 100% classification accuracy could 
Fig. 1 uTOP-seq and hmTOP-seq analysis of CV and cfDNA samples reveals a contribution of CV tissue to maternal cfDNA. a Total CG-coverage in 
cfDNA and CV tissue sample groups for the uCG and 5hmCG signals. Total log2 transformed sequencing coverage of autosomes was computed 
for each sample and ANOVA was used to test for differences in distributions across sample groups. b CG-fraction in cfDNA and CV tissue sample 
groups for the uCG and 5hmCG data. Fraction of CGs covered by at least one read to the total number of CGs was computed for each sample and 
ANOVA was used to test for differences in distributions across sample groups. c Non-metric multidimensional scaling plots of genome-wide signal 
distribution using two dimensions for uCG and 5hmCG data (using samples after the outlier removal). d Odds ratio (OR) for enrichment of uCG 
and 5hmCG data across genomic elements (p < 1.6 × 10–10). The genome was divided into 1,000-bp windows and total coverage per sample was 
averaged across sample groups for each window. Fisher’s exact test was used to test whether the windows with the 10% of the strongest signal are 
enriched with particular genomic elements. CGI, CG island; lincRNA, long intergenic non-coding RNA
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be achieved using both CG-coverage and CG-fraction 
parameters.
In uCG data, the Z-score of T21 pregnancies increased 
with higher fetal fraction consequently widening the gap 
between healthy and T21 pregnancies (r = 0.95, p = 0.013 
and r = 0.94, p = 0.015 for CG-fraction and CG-coverage, 
respectively; Pearson correlation), while the Z-scores of 
the healthy pregnancies did not show a significant trend. 
In 5hmCG data, there was a significant relationship 
between Z-score and fetal fraction among healthy but 
not among T21 pregnancies yet the difference between 
the two groups was higher than in uCG data (Fig.  3a, 
Additional file 2: Figure S1a). Notably, irrespective of the 
computational approach, the fetal fraction did not affect 
the diagnostic accuracy.
Next, in order to determine the minimal amount of 
reads necessary for detection of fetal aneuploidy we per-
formed an in silico analysis. We randomly sampled read 
counts from the original count matrix and repeated the 
analysis approach described above. For each subset size 
Fig. 2 Correlation of the reference fetal fraction and SeqFF prediction from a uTOP-seq and b hmTOP-seq data indicates the enrichment of cffDNA 
in maternal cfDNA mixture. Dashed line indicates linear regression. hmTOP-seq samples of shallow sequencing (on average 2.5 million (M) raw 
reads) are indicated with red circles and were not used in the estimation of Pearson correlation
Fig. 3 Detection of fetal trisomy T21 using CG-fraction. a Effect of fetal fraction on the Z-score indicating fetal karyotype. Normalized CG-fractions in 
chromosome 21 were used to compute Z-scores. 100% diagnostic accuracy of fetal trisomy T21 independent of fetal fraction was achieved. Dashed 
lines represent logistic regression fits. hmTOP-seq samples of shallow sequencing (2.5 million raw reads) are indicated with red circles. b Effect of 
reduced library size on classification accuracy. 100% diagnostic accuracy is achieved using 3 million or 1 million of processed sequencing reads of 
uTOP-seq and hmTOP-seq, respectively. Reads were randomly sampled and karyotype determined using leave-one-out cross-validation. In each 
cross-validation loop a logistic regression model was built with the Z-scores computed from the normalized CG-fraction within chromosome 21. 
Error bars indicate the standard deviation from mean AUC across 30 sampling iterations
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we performed the sampling 30 times. We found that 
5 million processed uTOP-seq reads were necessary 
to maintain perfect classification (area under curve, 
AUC = 1) using uCG-coverage in all 30 subsampling iter-
ations (Additional file 2: Figure S1b). Using uCG-fraction 
the subset could be further reduced to 3 million reads 
(Fig. 3b). Strikingly, 5hmCG data enabled the reduction 
of sample size to 1 million reads, maintaining AUC at 1 in 
all subsampling iterations (Fig. 3b, Additional file 2: Fig-
ure S1b).
We validated these calculations experimentally by 
including the four cfDNA samples of shallow sequencing 
mentioned above (cfDNA/healthy fetus, n = 2, cfDNA/
T21 fetus n = 2; 2.5 million raw reads and 1.3 million 
processed reads). We combined the low coverage sam-
ples with the original ones subsampled down to 1 million 
reads and observed 100% classification accuracy across 
all samples (Fig. 3a, Additional file 2: Figure S1a). Thus, 
this analysis demonstrated a superior diagnostic poten-
tial of hmTOP-seq at high and low sequencing depths.
Placenta‑specific differentially modified regions are 
informative of fetal karyotype
We next sought to identify fetal-specific differentially 
modified regions (DMRs) that would discriminate 
between cfDNA of NPCs and both cfDNA of healthy 
pregnancies and CVS. We partitioned the chromosome 
21 into 100 bp-wide non-overlapping windows. For each 
window we computed the CG-coverage and the CG-frac-
tion and normalized by the CG-coverage and CG-frac-
tion in the reference chromosomes 16 and 20, as above.
First, we obtained the pregnancy-specific uCG DMRs 
by comparing NPCs with cfDNA samples of healthy 
pregnancies. Using logistic regression with the nor-
malized CG-coverage and CG-fraction as independent 
variables we identified 2,761 pregnancy-specific DMRs 
(FDR q < 0.05). Next, by comparing NPCs and CVS we 
obtained 16,555 CV-specific DMRs (FDR q < 0.05; logis-
tic regression). The same analytic approach did not yield 
FDR-significant DMRs from hmTOP-seq data. Therefore, 
we used nominal p < 0.05 threshold and identified 4,930 
pregnancy-specific 5hmCG DMRs and 15,986 CV-spe-
cific 5hmCG DMRs. For both uCG and 5hmCG DMR 
sets, the overlap between the pregnancy-specific and 
CV-specific DMRs was larger than could be expected by 
chance alone. We termed the overlapping sets the pla-
centa-specific DMRs (n = 2,164; OR = 43, and n = 1,589; 
OR = 5.5, for uCG and 5hmCG, respectively; p < 1 × 10–
16; Fig. 4a). For the placenta-specific uCG DMRs, the dif-
ference between NPCs and cfDNA samples of pregnant 
women was concordant with the difference between 
NPCs and CV samples (r = 0.82 and r = 0.89, for CG-cov-
erage and CG-fraction, respectively; Pearson correlation). 
Similar results were observed for 5hmCG DMRs (r = 0.8 
and r = 0.8, for CG-coverage and CG-fraction, respec-
tively; Pearson correlation; Fig. 4b).
To test whether the identified DMRs can be influenced 
by genetic variability, we calculated their overlap with 
methylation quantitative trait loci (mQTL) probes from 
ARIES database [30]. ARIES mQTL probes identified 
across chromosome 21 in cord blood and blood of preg-
nant women (birth and pregnancy mQTLs, respectively) 
were not significantly enriched within the DMR groups 
(all p values from Fisher’s exact test > 0.05). Moreover, 
both groups of mQTLs overlapped less than 1% of DMRs, 
irrespective of the DMR group.
The placenta-specific uCG and 5hmCG DMRs over-
lapped different genomic elements as could be predicted 
from the distinct genomic distribution of hypomethyl-
ated and 5-hydroxymethylated CGs in various tissues [21, 
31]. uCG DMRs were enriched in placental enhancers, 
promoter CGIs, promoters of lincRNAs and protein-cod-
ing genes, and 5′UTRs. In contrast, 5hmCG DMRs were 
enriched in coding exons, 3′UTR and introns (Fig. 4c).
Next, we asked whether the placenta-specific DMRs 
are informative of fetal trisomy T21. Using leave-one-out 
cross-validation we constructed and evaluated a logistic 
regression model [32] for each placenta-specific DMR 
with the CG-coverage and CG-fractions as independent 
variables and fetal karyotype as the response variable. In 
total, we discovered 376 uCG and 496 5hmCG DMRs in 
chromosome 21 that classified the samples according to 
fetal karyotype with 100% accuracy (AUC = 1; Additional 
file 3: Table S2).
Differential T21‑specific modifications overlap known 
Down syndrome associated genes
Considering epigenetic changes in Down syndrome 
affected fetuses [33], we evaluated modification differ-
ences between cfDNA samples of healthy and T21-diag-
nosed pregnancies and computed the T21-specific 
DMRs. A logistic regression model was fitted to each 
100  bp window with the CG-coverage and CG-fraction 
as independent variables and karyotype as the response 
variable, as above. In addition, we adjusted for possible 
confounding effects of fetal fraction and fetal sex which 
could not be accounted for in the previous analyses. We 
identified 3,490 uCG and 2,002 5hmCG DMRs (FDR 
q < 0.05; logistic regression), of which only 82 overlapped 
between the two datasets (OR = 2.3, p = 1.1 × 10–10) 
(Additional file 4: Table S3).
216 and 124 DMRs overlapped between the T21 and 
placenta-specific DMR sets for uCG and 5hmCG, respec-
tively (OR = 6.1 and OR = 8.2, respectively; p < 2.2 × 10–
16), demonstrating that different DMR identification 
strategies lead to different DMR sets in chromosome 21 
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which can be complementary for detecting fetal karyo-
type. The T21-affected pregnancies showed increased 
CG-coverage and CG-fraction across the uCG and 
5hmCG DMR sets as compared to the signals in healthy 
pregnancies which points to increased DNA demethyla-
tion in the T21 fetuses (Fig. 4d).
Interestingly, both uCG and 5hmCG DMR datasets bet-
ter overlapped the pregnancy-specific DMRs (OR = 6.6 
and OR = 9, for uCG and 5hmCG, respectively) than the 
CV-specific DMRs (OR = 2.4 and OR = 2.9 for uCG and 
5hmCG, respectively; for all comparisons p < 1 × 10–16). 
This result might be caused by the same tissue source of 
DNA or could suggest that fetal tissues other than the 
placenta-derived trophoblasts might contribute to the 
cfDNA mixture of maternal blood.
To test for a possible genotype influence, we compared 
the identified T21 DMR sets with birth or pregnancy 
mQTL loci. Both mQTL groups were not significantly 
Fig. 4 Analysis of fetal-specific and T21-specific differentially modified regions. a Venn diagrams indicating the overlap of the pregnancy-specific 
and CV-specific DMRs that constitute the placenta-specific DMR sets for uCG and 5hmCG data. b Pearson correlation of the modification differences 
observed in the placenta-specific DMRs. Pregnancy-specific changes on the x-axis indicate modification differences between NPCs and cfDNA 
samples of pregnant women. CV-specific changes on the y-axis indicate modification differences between NPCs and CVS. c Enrichment of 
genomic elements for the placenta-specific and T21-specific DMRs using Fisher’s exact test. CGI, CG island; lincRNA, long intergenic non-coding 
RNA. d T21-specific DMRs exhibit higher CG-coverage and CG-fraction differences than non-differentially modified regions. logFC represents a log 
fold-change difference between T21-diagnosed pregnancies and healthy pregnancies
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enriched (Fisher’s exact test p value > 0.05) and covered 
only ~ 0.5% of identified DMRs.
Enrichment of genomic elements across the T21-spe-
cific DMRs was similar to that of the pregnancy-specific 
DMRs: uCG DMRs were significantly enriched towards 
the 5′ end of protein-coding genes (OR = 2.4, and 
OR = 2.5 for 5′UTR and promoter CGIs, respectively), 
while 5hmCG DMRs showed enrichment for genic CGIs 
(OR = 3) and placental enhancers (OR = 2.9) (Fig.  4c). 
Furthermore, distribution of the T21-specific DMRs 
along chromosome 21 was different for the uCG and 
5hmCG datasets (p = 1.6 × 10–12; Kolmogorov–Smirnov 
test); most of the identified 5hmCG DMRs tended to 
cluster at the end of the long arm, whereas the uCG 
DMRs were more evenly distributed along the long arm 
of chromosome 21 (Additional file  2: Figure S2). 46% 
and 64% of the uCG and 5hmCG T21-specific DMRs, 
respectively, overlapped protein-coding genes. Interest-
ingly, the above-mentioned 82 regions common for the 
T21-specific uCG and 5hmCG DMR sets showed very 
high enrichment for coding exons (OR = 4.4, p = 8 × 10–
4). These exons corresponded to 7 genes, 3 of which have 
been previously associated with Down syndrome: GART 
[34], DNMT3L [35] and AIRE [36] (Additional file  4: 
Table S3). In summary, our analyses revealed widespread 
epigenetic changes in T21 fetuses that could be targeted 
for efficient prenatal diagnostics of fetal disorders from 
maternal cfDNA mixture.
Detection of T21‑specific differentially modified CGs 
by qPCR
An investigation of differentially modified uCGs and 
5hmCGs in chromosome 21 of cfDNA samples of 
T21-diagnosed pregnancies against the three types of 
control samples—CV DNA, cfDNA of healthy preg-
nancies and NPCs,—has led to the selection of the 
fetal T21-specific differentially modified individual 
CGs (or CG-DMRs) that could be used for detection 
of fetal T21. The modification state of these CG-DMRs 
as well as any selected CG site across the above-men-
tioned DMR regions can be evaluated by sequencing or, 
alternatively, by qPCR. We measured the modification 
state and enrichment of the selected T21-specific CG-
DMRs (Additional file  5: Table  S4) and their adjacent 
genomic regions in uTOP-seq and hmTOP-seq libraries 
by qPCR. To assess the variability in CG-DMR modifi-
cation status between individuals, we applied the qPCR 
assay of four selected uCG-DMRs and three 5hmCG-
DMRs for a group of cfDNA samples of healthy and 
T21-affected pregnancies which included sequenced 
samples and additional non-sequenced samples. Nota-
bly, all tested  regions discriminated well between T21 
and healthy pregnancies (Fig.  5). Overall, we demon-
strated that fetal trisomy 21 can be detected by test-
ing a single differentially modified uCG or 5hmCG site 
using qPCR analysis.
Fig. 5 Detection of T21-specific CG-DMRs by qPCR. Relative quantification of individual T21-specific a uCG-DMRs and b 5hmCG-DMRs located 
on chromosome 21 using qPCR for replicated cfDNA samples of women pregnant with healthy or T21-diagnosed fetuses. The y-axis indicates the 
threshold cycle values  (CT) calculated in qPCR for the regions selected from Table S4 whose genome coordinates are shown above the graphs. 
Numerical values of  CT inversely correlate to the abundance of the DMR region, indicating higher abundance of the region in the cfDNA samples of 
pregnant females carrying a T21-diagnosed fetus. Only samples which showed  CT values above the set threshold  (CT values ≤ 34) were included in 
the graphs. P-values indicated above were calculated using t-test
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Discussion
NIPT based on massive parallel sequencing of maternal 
cfDNA for detecting fetal chromosomal aneuploidies has 
already become integrated into clinical practice. Cost of 
testing could be significantly lowered by targeting DNA 
molecules of fetal origin and thus reducing the neces-
sary analytical read count. Uncovering the presence of 
megabase-size placenta hypomethylated domains [13] 
raised an idea to employ our recently developed uTOP-
seq strategy [24] for analysis of unmethylated CG sites. 
In this study, for the first time to our knowledge, we 
demonstrated the covalent derivatization and targeted 
sequencing of uCG sites in maternal cfDNA with the aim 
to detect fetal karyotype. Robust covalent labelling and 
high sensitivity of the uTOP-seq approach enabled detec-
tion of fetal T21 using input cfDNA amounts as low as 
5  ng and only 3 million of processed sequencing reads 
(approx. 6 million raw reads). Such shallow sequenc-
ing depth is up to 10 times lower than that of standard 
whole-genome MPS-based NIPT. This is an important 
milestone in the future development of an affordable epi-
genetic NIPT test based on sequencing.
The second important milestone of our study is the 
first known to date demonstration that 5hmC profil-
ing in maternal cfDNA can accurately inform on fetal 
karyotype. The hmTOP-seq method [25], which cova-
lently targets 5hmC residues, enabled the construction 
of genome-wide 5hmC maps of relatively low 5hmC 
levels in CV samples and cfDNA. Most importantly, we 
observed that hmTOP-seq was most discriminatory in 
detection of T21 fetuses independently of fetal fraction. 
It also allowed decreasing the analytical read count down 
to 1 million processed reads while keeping the diagnos-
tic accuracy at 100%. Therefore, we suggest that prenatal 
tests based on 5hmCG analysis could potentially maxi-
mize the diagnostic sensitivity in relation to cost and 
could be an optimal choice for the sequencing-based 
epigenetic approaches of NIPT. Furthermore, we demon-
strated that fetal fraction can be measured directly from 
the read count of hmTOP-seq and uTOP-seq using a 
computational method that estimates fetal fraction inde-
pendent of fetal sex.
We identified a large panel of placenta-specific uCG- 
and 5hmCG-biomarkers and utilized them for detec-
tion of fetal karyotype. To ascertain global methylation 
changes in T21 fetuses [33], we also included the com-
putation of DMRs specific for the T21-affected fetuses. 
Interestingly, these DMRs better overlapped the healthy 
pregnancy-specific DMR sets than those of CV-specific 
DMRs, suggesting that DNA fragments of other tissue-
origin than placenta might contribute to cffDNA. This 
points to a need for future comprehensive investigation 
of the tissue composition of maternal cfDNA. Analysis of 
the pregnancy-specific and T21-specific DMRs indicated 
the highly perturbed epigenome of T21-affected fetuses. 
Thus, disease-specific epigenetic characteristics should 
certainly be taken into account for the development 
of reliable NIPT of fetal aneuploidies, including T21. 
Importantly, we also demonstrated the informativeness 
of a PCR-based assay aimed at the analysis of individual 
CGs for testing the T21-specific modification changes.
Further validation of our approaches in a large clini-
cal cohort is necessary. Additionally, the study needs to 
be expanded to other common fetal aneuploidies such as 
Patau and Edwards syndromes. For wider future appli-
cability of our methods, we calculated DMRs in chro-
mosomes 13 and 18 using the same strategy for DMR 
identification resulting in tissue-specific and pregnancy-
specific DMR data sets (Additional file  2: Figure S3). 
Although the selected best DMRs demonstrated the 
obvious difference in signal between the sample groups, 
these DMRs should be validated in a clinical setting.
NIPT as a clinical application should be provided in 
a cost-effective and timely manner. In principle, any 
NIPT analysis includes three stages: sample prepara-
tion, sequencing (or qPCR) and data analysis. As library 
preparation time for both MPS- and TOP-seq-based 
protocols is comparable (up to 6  h), the number of 
required sequencing reads highlights the possible cost-
effectiveness of the TOP-seq approaches. In contrast 
to whole-genome shallow coverage NIPT that requires 
approximately 10–20 million reads [37, 38] for high-
quality karyotyping, TOP-seq allows accurate predic-
tion of fetal karyotype with as low as 1 million single-end 
reads. Another advantage of TOP-seq is the simplicity 
of data analysis. Only a fraction (0.6–0.9  M) of total 28 
million CG sites in human genome are analyzed in shal-
low sequencing TOP-seq. Moreover, chromosome 21 
Z-score calculations were based on 10–13 thousand CG 
sites. Due to the relatively  small  number of the neces-
sary sequencing reads per patient, the analytical pipeline 
does not require considerable computational resources 
and Z-score calculations could be done on a conventional 
desktop personal computer. Additional possible cost and 
time savings can be realized if a TOP-seq based qPCR 
assay is applied for NIPT. It would open the way for wider 
accommodation of NIPT at any lab or clinics.
Conclusions
Although our study is limited by its sample size (48 sam-
ples in total), it demonstrated a potential of the uCG- 
and 5hmCG-based epigenetic analysis for NIPT of fetal 
aneuploidy. We detected fetal trisomy of chromosome 
21 with an excellent specificity/sensitivity using both 
chromosome-wide data and regional modification differ-
ences. The same analytic approach may be exploited for 
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identification of regions featuring other chromosomal, 
genetic or epigenetic abnormalities. Although MPS for 
NIPT is of higher cost than qPCR-based interrogation 
of selected cfDNA regions [39–41], we suggest that an 
affordable test based on targeted sequencing of epigenet-
ically distinct fetal DNA could provide more information 
on various genetic and epigenetic abnormalities and thus, 
is a preferred strategy for NIPT.
Methods
Sample acquisition, sequencing and SeqFF
A total of 21 blood plasma samples for cfDNA from 
pregnant women were collected at Tartu University Hos-
pital (Tartu, Estonia). Seven of these women were carry-
ing fetuses with trisomy 21. All samples were obtained 
from the pregnant women with the gestational age of 
12–20  weeks with singleton pregnancy and undergoing 
the low-coverage NIPT whole-genome MPS sequenc-
ing using Illumina technology as previously described 
[37, 42]. SeqFF was used for calculating the cell-free fetal 
DNA fraction for all the samples [27]. Fetal trisomy 21 
was confirmed using either amniocentesis or chorionic 
villus sampling. In addition, blood plasma samples for 
cfDNA were obtained from ten non-pregnant women. 
Seven chorionic villi tissue samples were obtained from 
first trimester voluntary termination of pregnancy. 
cfDNA from maternal blood samples was extracted 
using QIAamp DNA blood Midi Kit (QIAGEN), and 
genomic DNA from chorionic villi tissue and blood was 
extracted by phenol–chloroform extraction.
cfDNA and CV DNA processing by uTOP‑seq 
and hmTOP‑seq
In uTOP-seq, 4–10  ng of cfDNA (or 100  ng of CV tis-
sue DNA, sheared to 200 bp by Covaris sonicator) were 
labeled with 0.11  μM eM.SssI [23] in 10  mM Tris–HCl 
(pH 7.4), 50  mM NaCl, 0.5  mM EDTA buffer supple-
mented with 200 μM Ado-6-azide cofactor [43] for 1 h at 
30 °C followed by thermal inactivation at 65 °C for 20 min 
and Proteinase K treatment (0.2  mg/ml) for 30  min at 
55  °C and finally column purified (GeneJET PCR puri-
fication kit, Thermo Fisher Scientific (TS)). In hmTOP-
seq, 5hmC glycosylation was carried out  with 5–10  ng 
of cfDNA (or 200  ng of CV tissue DNA, sheared to 
200 bp by Covaris sonicator) supplemented with 50 µM 
UDP-6-azide-glucose (Jena Bioscience) and 2.5–5 U 
T4 β-glucosyltransferase (TS) for 1  h 37  °C followed by 
enzyme inactivation at 65 °C for 20 min and column puri-
fication (GeneJET PCR Purification kit (TS)). After liga-
tion of the partially complementary adapters as described 
previously (step 2, [24]), covalently labeled DNA was 
supplemented with 20  µM alkyne-containing DNA oli-
gonucleotide (which was biotinylated for 5hmC analysis) 
(5′-T(alkyneT)TTT TGT GTG GTT TGG AGA CTG ACT 
ACC AGA TGT AAC A-(biotin)-3′, Base-click) and 8  mM 
CuBr: 24 mM THPTA mixture (Sigma) in 50% of DMSO, 
incubated for 20 min at 45  °C and subsequently diluted 
to < 1.5% DMSO before column purification (GeneJET 
NGS Cleanup Kit, Protocol A (TS)). DNA recovered after 
the biotinylation step was incubated with 0.1 mg Dyna-
beads MyOne C1 Streptavidin (TS) in buffer A (10 mM 
Tris–HCl (pH 8.5), 1 M NaCl) at room temperature for 
3 h on a roller. DNA-bound beads were washed 2 × with 
buffer B (10  mM Tris–HCl (pH 8.5), 3  M NaCl, 0.05% 
Tween 20); 2 × with buffer A (supplemented with 0.05% 
Tween 20); 1 × with 100  mM NaCl and finally resus-
pended in water and heated for 5 min at 95 °C to recover 
the enriched DNA fraction. Purified DNA after oligonu-
cleotide conjugation (uCG) or biotin-enrichment (5hmC) 
was subsequently used in a priming reaction with 1 U Pfu 
DNA polymerase (TS), 0.2  mM dNTP, 0.5  μM comple-
mentary priming strand (EP; 5′-TGT TAC ATC TGG TAG 
TCA GTC TCC AAA CCA CACAA-3′, with custom LNA 
modifications (Exiqon) and phosphorothioate linkages 
at the 3′ end). Priming reaction mixture was incubated at 
the following cycling conditions: 95 °C 2 min; 5 cycles at 
95  °C 1 min, 65  °C 10 min, 72  °C 10 min. Amplification 
of a primed DNA library was carried out by adding the 
above reaction mixture to 100 μl of amplification reaction 
containing 50  µl of 2 × Platinum SuperFi PCR Master 
Mix (TS) and barcoded fusion PCR primers A(Ad)-EP-
barcode-primer (63 nt) and trP1(Ad)-A2-primer (45 nt) 
at 0.5 μM each (both primers contained phosphorothio-
ate modifications). Thermocycler conditions: 94 °C 4 min; 
15 cycles (uCG cfDNA), or 17 cycles (5hmC cfDNA), or 
12 cycles for CV DNA at 95 °C 1 min, 60 °C 1 min, 72 °C 
1 min. The final libraries were size-selected for ~ 270 bp 
fragments (MagJET NGS Cleanup and Size Selection Kit, 
(TS)), and their quality and quantity were tested on 2100 
Bioanalyzer (Agilent). Libraries were subjected to Ion 
Proton (TS) sequencing.
Processing of sequencing data
Raw uTOP-seq and hmTOP-seq sequencing reads were 
processed as described in [24] except for the 3′ sequence 
ends, where adapter sequences were trimmed only if they 
were identified using cutadapt with maximum allowed 
error rate 0.1 [44]. Processed reads were mapped to refer-
ence human genome version hg19 and coverage for each 
CG dinucleotide was computed as the total number of 
reads starting from or within 3 bp of the dinucleotide on 
either of the strands. On average, 40% of raw reads were 
retained for downstream analysis per sample.
Outlier identification was performed separately for 
uCG and 5hmC samples. CG coverage matrices were 
transformed using Hellinger transformation [45] and 
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then represented in two-dimensional space using non-
metric multidimensional scaling (nMDS) with Bray–Cur-
tis similarity index [46]. Samples that were further than 
two standard deviations away from the mean of their own 
sample group (cfDNA of NPCs, pregnancy cfDNA, CVS) 
in either nMDS1 or nMDS2 dimension were deemed 
outliers and removed from further analysis. There were 
three outlying samples in uCG and one in 5hmCG data-
set: two in 20 uCG cfDNA samples, one in 7 uCG CV 
samples and one 5hmCG sample was removed from 21 
5hmCG cfDNA samples (including the samples of shal-
low sequencing).
Karyotype detection from uCG and 5hmCG data
Chromosome-wide coverage was defined as the sum 
of uTOP-seq or hmTOP-seq coverage across all identi-
fied CGs pertaining to a chromosome. A CG-fraction 
was defined as the ratio of CG dinucleotides covered by 
at least one uTOP-seq or hmTOP-seq read to the total 
number of CGs in a chromosome. Z-scores were calcu-
lated following [29]. Briefly, for a sample i, value Xi,21/r 
was defined as the ratio of signal (either CG-coverage 
or identified CG-fraction) between chromosome 21 
and a reference chromosome, r. We then used Xi,21/r to 
compute the mean, μ, and standard deviation, σ, of the 
healthy control subpopulation of samples. Then, for each 
sample i, we calculated Z-score as Zi, 21/r = (Xi.21/r − μ)/σ. 
We found that the results were most stable and consist-
ent, when chromosome 20 and chromosome 16 for uCG 
and 5hmCG data, respectively, were used as references.
In silico subsampling of libraries was performed by ran-
domly selecting a set of processed reads that have been 
assigned to a CG site. For each subset size, 30 subsampled 
datasets were produced and karyotype prediction mod-
els were trained and evaluated on each of them. Model 
training and evaluation was performed using leave-one-
out cross-validation. For each cross-validation cycle one 
sample was set aside and a logistic regression model 
was built using the Z-scores computed on the remain-
ing samples. In 5hmCG data, when subset size was equal 
or below one million reads, we also included the shallow 
sequencing samples (2.5  M raw reads) into the evalua-
tion loop. The model was then used to predict the karyo-
type of the retained sample. Once the karyotypes of all 
samples were obtained, the accuracy of prediction was 
evaluated as the area under the receiver-operator curve 
(AUC). Area AUC = 1 (i.e. 100%) indicates perfect clas-
sification accuracy.
Identification of differentially modified regions
The chromosome 21 was partitioned into 100-bp non-
overlapping windows. For each window log trans-
formed CG-coverage and CG-fraction was calculated. 
CG-coverage was normalized by the total read count in 
a reference chromosome. CG-fraction was normalized 
by the overall identified fraction in a reference chro-
mosome. Chromosomes 20 and 16 were used as refer-
ences for uCG and 5hmCG data, respectively. Next, for 
each window two logistic regression models were fitted. 
Full model included CG-coverage, CG-fraction, and, for 
T21-specific DMRs, fetal sex and fetal fraction, as inde-
pendent variables. CG-coverage and CG-fraction were 
excluded from the null model. ANOVA Chi-squared test 
was used to compare full and null models to obtain p 
value. In cases where models did not converge, fetal sex 
was removed. FDR was used to adjust p values for multi-
ple testing and q < 0.05 was used as a significance thresh-
old, if not specified otherwise.
For each placenta-specific DMR, leave-one-out cross-
validation procedure was performed as described above 
in order to determine its ability to diagnose T21. For 
each cross-validation cycle, Bayesian generalized linear 
model [32] with normalized CG-coverage and CG-frac-
tion as independent variables was constructed. DMRs 
with AUC = 1 were selected as discriminatory of fetal 
karyotype.
Enrichment analyses
Enrichment of genomic elements with the strongest 
signal was calculated as follows. First, the genome was 
divided into 1 kb-wide non-overlapping windows. Within 
each window total coverage was computed per sample. 
The total coverage values were then averaged per group 
of samples (cfDNA of NPCs, pregnancy cfDNA samples, 
CVS) and windows falling among top 10% most covered 
windows were designated as those having the highest sig-
nal. Then, contingency table was computed for each CG 
falling into one of the highest signal windows and over-
lapping a genomic region. Fisher’s exact test was per-
formed to estimate the odds ratio and p value.
Enrichment of DMRs with genomic regions was com-
puted by forming a contingency table which  contained 
information whether each DMR  is significant and over-
laps genomic regions of interest. As above, Fisher’s exact 
test was used to estimate the odds ratios and p values. 
Placental enhancer regions were downloaded from the 
enhancer atlas [47]. Gene annotations were downloaded 
from the GENCODE genes and promoters were defined 
as regions 2 kb upstream from the gene start [48]. Human 
genome annotation (build hg19), CGI and repeat data-
sets were downloaded from the UCSC database (https ://
genom e.ucsc.edu).
Birth and pregnancy mQTLs were retrieved from the 
ARIES mQTL database followed by the selection of only 
high-quality probes [30, 49]. In total, there were 4243 
Illumina Infinium HM450 array probes in chromosome 
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21 and 2642 after selecting only high-quality probes (238 
birth mQTL and 291 pregnancy mQTLs). Enrichment of 
mQTL probes with DMRs was calculated by creating a 
contingency table which evaluated whether each Illumina 
Infinium HM450 array probe is an mQTL and overlaps a 
DMR.
Chromosome 21 ideogram was plotted using karyop-
loteR R package [50]. Computational analyses were per-
formed using R version 3.5 [51].
Quantitative liquid chromatography coupled with tandem 
mass spectrometry (HPLC–MS/MS) analysis of genomic 
DNA
100–500 ng of blood and CV tissue genomic DNA [n = 2 
CV; n = 3 blood (with two technical replicates)] sam-
ples were digested with 0.5 U Nuclease P1 (Sigma) for 
2 h at 55 °C in 40 µl of P1 buffer, then dephosphorylated 
by adding 1  μl FastAP (TS) phosphatase and incubated 
overnight at 37  °C. Samples were analyzed on an inte-
grated HPLC/ESI-QQQ system (Agilent) equipped with 
a Supelco Discovery®HS C18 column (7.5 cm × 2.1 mm, 
3  μm) by elution with a linear gradient of solvents A 
(0.0075% formic acid in water) and B (0.0075% formic 
acid in acetonitrile) at a flow of 0.3  ml/min at 30  °C as 
follows: 0–6  min, 0% B; 6–18  min, 10% B; 18–20  min, 
100% B. Mass spectrometer was operating in the positive 
ion MRM mode and intensities of nucleoside-specific 
ion transitions were recorded: d5mC m/z 242.1 → 126.1; 
d5hmC m/z 258.1 → 142.1; dG m/z 268.1 → 152.1. Ioni-
zation capillary voltage was set to 1800 V, drying gas tem-
perature 300  °C and flow rate 10  l/min, collision energy 
15 V. Standard d5mC, d5hmC and dG nucleosides (Tri-
link Biotech) were used for external calibration. d5hmC 
calibration curves were constructed by plotting ion 
counts against different concentrations of d5hmC stand-
ards and linear plots were obtained with R2 values of 
0.999. To account for input DNA differences, DNA sam-
ple normalization according to dG was performed. Data 
was analysed using Agilent MassHunter software and 
Microsoft Excel.
Detection of fetal trisomy T21 by qPCR
The difference in labeling intensity at specific CG-DMRs, 
shown in Additional file 5: Table S4, was tested in female 
cfDNA carrying healthy or T21-diagnosed fetuses. 0.5 ng 
of the final uTOP-seq and hmTOP-seq libraries were 
used for measurement of the labeling intensity of uCGs 
and 5hmCGs by qPCR with a Rotor-Gene Q real-time 
PCR system (Qiagen) using Maxima Sybr Green/ROX 
qPCR Master Mix (TS). 0.3  mM of each primer pair 
(shown in Additional file  5: Table  S4) was used in each 
reaction, wherein one of the primers binds to a genomic 
region nearby a  CG site, and another primer binds in 
vicinity of the same CG to allow PCR amplification of the 
region to occur. The amplification conditions were set 
as: 95  °C for 10 min, 40 cycles 95  °C for 15  s, 60  °C for 
60  s. Due to high methylation and absence of hydroxy-
methylation of the selected CG-DMRs in healthy preg-
nancy cfDNA samples, these samples often do not show 
the respective amplification product (no or ambiguous 
products on electrophoresis gels and in melting curves). 
Therefore, the loci which amplify above the experimental 
values of  CT 34  (CT values ≤ 34) were treated as detected 
in a qPCR test and only samples which showed  CT values 
above the set threshold were included in Fig. 5.
Supplementary information
Supplementary information accompanies this paper at https ://doi.
org/10.1186/s1314 8-020-00938 -x.
Additional file 1: Table S1. DNA sample information.
Additional file 2: Figure S1. Detection of fetal trisomy T21 using CG-
coverage. (a) Effect of fetal fraction on the Z-score indicating fetal karyo-
type. Total normalized chromosome 21 coverage was used to compute 
Z-scores. Dashed lines represent logistic regression fits. 100% diagnostic 
accuracy of fetal trisomy T21 computed using CG-coverage of chromo-
some 21 is independent of fetal fraction. hmTOP-seq samples of shallow 
sequencing (2.5 million reads) are indicated with red circles. (b) Effect of a 
reduced library size on classification accuracy. 100% diagnostic accuracy 
is achieved using 5 million or 1 million of processed sequencing reads in 
uTOP-seq and hmTOP-seq, respectively. Reads were randomly sampled 
and karyotype determined using a leave-one-out cross-validation. In each 
cross-validation loop a logistic regression model was built with Z-scores 
computed from normalized chromosome coverage. Error bars indicate 
the standard deviation from mean AUC across 30 sampling iterations. 
Figure S2. Distribution of T21-specific DMR. Ideogram of chromosome 21 
(centromeric region marked in red) showing distributions of the T21-spe-
cific uCG and 5hmCG DMRs. DMRs shared between the sets are indicated 
with dark vertical bars. 7 genes containing the shared DMRs across their 
exons are specified above the graph. Figure S3. Difference in (a) uCG and 
(b) 5hmCG signal across the selected DMRs identified for chromosome 13 
and chromosome 18 between CV tissue DNA of the 1st trimester fetuses 
and cfDNA samples of NPCs; and between NPCs and pregnant female 
carrying a healthy fetus. The genomic coordinates of DMRs are shown 
above the graphs. For chromosome 13, we obtained 1394 pregnancy-
specific uCG DMRs (FDR q < 0.05) and 25,091 tissue-specific uCG DMRs 
(FDR q < 0.05; logistic regression) and using nominal p < 0.05 threshold, 
4255 pregnancy-specific 5hmCG DMRs and 22,526 tissue-specific 5hmCG 
DMRs. For chromosome 18, we obtained 1321 pregnancy-specific uCG 
DMRs (FDR q < 0.05), 22,121 tissue-specific uCG DMRs (FDR q < 0.05; 
logistic regression) and 3626 pregnancy-specific 5hmCG DMRs and 20,780 
tissue-specific 5hmCG DMRs.
Additional file 3: Table S2. List of the identified DMRs with AUC = 1.
Additional file 4: Table S3. T21-specific DMRs common for uCG and 
5hmCG data.
Additional file 5: Table S4. Selected fetal T21-specific CG-DMRs.
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